TW200613009A - Capsule having chewing stability - Google Patents

Capsule having chewing stability

Info

Publication number: TW200613009A
Authority: TW; Taiwan
Prior art keywords: capsule; capsule film; thickness; chewing; easy
Prior art date: 2004-06-11

Application number

TW094119016A

Other languages

English (en)

Inventor

Ichiro Okamoto

Yuji Miyamoto

Hidekatsu Nishimura

Original Assignee

Ono Pharmaceutical Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-06-11

Filing date

2005-06-09

Publication date

2006-05-01

2005-06-09 Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co

2006-05-01 Publication of TW200613009A publication Critical patent/TW200613009A/zh

Links

239000002775 capsule Substances 0.000 title abstract 6
230000001055 chewing effect Effects 0.000 title abstract 2
239000007901 soft capsule Substances 0.000 abstract 2
YCYMCMYLORLIJX-SNVBAGLBSA-N (2r)-2-propyloctanoic acid Chemical compound CCCCCC[C@H](C(O)=O)CCC YCYMCMYLORLIJX-SNVBAGLBSA-N 0.000 abstract 1
230000003187 abdominal effect Effects 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
210000002784 stomach Anatomy 0.000 abstract 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Psychiatry (AREA)
Oncology (AREA)
Virology (AREA)
Psychology (AREA)
Communicable Diseases (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Tropical Medicine & Parasitology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Diabetes (AREA)
AIDS & HIV (AREA)
Hematology (AREA)
Hospice & Palliative Care (AREA)
Molecular Biology (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Inorganic Chemistry (AREA)

TW094119016A 2004-06-11 2005-06-09 Capsule having chewing stability TW200613009A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2004174576		2004-06-11
JP2005122821		2005-04-20

Publications (1)

Publication Number	Publication Date
TW200613009A true TW200613009A (en)	2006-05-01

Family

ID=35502808

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW094119016A TW200613009A (en)	2004-06-11	2005-06-09	Capsule having chewing stability

Country Status (13)

Country	Link
US (1)	US20080057115A1 (zh)
EP (1)	EP1754479A4 (zh)
JP (1)	JP5615478B2 (zh)
KR (1)	KR20070024722A (zh)
AU (1)	AU2005251623A1 (zh)
BR (1)	BRPI0512000A (zh)
CA (1)	CA2569746A1 (zh)
IL (1)	IL179967A0 (zh)
MX (1)	MXPA06014396A (zh)
NO (1)	NO20065670L (zh)
RU (1)	RU2384325C2 (zh)
TW (1)	TW200613009A (zh)
WO (1)	WO2005120490A1 (zh)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH08376Y2 (ja)	1990-08-15	1996-01-10	株式会社アルメックス	不溶解性陽極を用いたメッキ装置
WO2007123153A1 (ja) *	2006-04-19	2007-11-01	Ono Pharmaceutical Co., Ltd.	経口投与用カプセル
EP4137128A1 (en)	2008-09-02	2023-02-22	Amarin Pharmaceuticals Ireland Limited	Pharmaceutical composition comprising eicosapentaenoic acid and a statin, and methods of using same
US9504274B2 (en)	2009-01-27	2016-11-29	Frito-Lay North America, Inc.	Methods of flavor encapsulation and matrix-assisted concentration of aqueous foods and products produced therefrom
MX350088B (es)	2009-04-29	2017-08-25	Amarin Pharma Inc	Composicion farmaceutica estable y metodos de uso de la misma.
NZ720946A (en)	2009-04-29	2017-09-29	Amarin Pharmaceuticals Ie Ltd	Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
CN108096209A (zh)	2009-06-15	2018-06-01	阿马里纳制药公司	在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl-c水平的组合物和方法
US20110071176A1 (en)	2009-09-23	2011-03-24	Amarin Pharma, Inc.	Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
NZ712068A (en)	2010-11-29	2017-03-31	Amarin Pharmaceuticals Ie Ltd	Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en)	2010-11-29	2023-08-01	Amarin Pharmaceuticals Ireland Limited	Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US8974594B2 (en) *	2011-03-29	2015-03-10	Empire Technology Development Llc	Microcapsule corrosion control in reinforced concrete
US20120251484A1 (en)	2011-03-31	2012-10-04	Cp Kelco Aps	Cold prepared gel and method for making same
US11291643B2 (en)	2011-11-07	2022-04-05	Amarin Pharmaceuticals Ireland Limited	Methods of treating hypertriglyceridemia
US20130131170A1 (en)	2011-11-07	2013-05-23	Amarin Pharmaceuticals Ireland Limited	Methods of treating hypertriglyceridemia
ITMI20112221A1 (it) *	2011-12-05	2013-06-06	Altergon Sa	Formulazioni stabili in capsule di gelatina molle di antiaggreganti piastrinici, acidi grassi omega-3 e amilosio
ES2891473T3 (es)	2012-01-06	2022-01-28	Amarin Pharmaceuticals Ie Ltd	Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto
CA3067012C (en)	2012-06-29	2021-10-05	Amarin Pharmaceuticals Ireland Limited	Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
WO2014074552A2 (en)	2012-11-06	2014-05-15	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US20140187633A1 (en)	2012-12-31	2014-07-03	Amarin Pharmaceuticals Ireland Limited	Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en)	2013-02-06	2016-09-27	Amarin Pharmaceuticals Ireland Limited	Methods of reducing apolipoprotein C-III
US9624492B2 (en)	2013-02-13	2017-04-18	Amarin Pharmaceuticals Ireland Limited	Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9283201B2 (en)	2013-03-14	2016-03-15	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) *	2013-03-15	2014-09-18	Amarin Pharmaceuticals Ireland Limited	Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US9364441B2 (en)	2013-05-23	2016-06-14	Barlean's Organic Oils, Llc	Rotary die system
US10966968B2 (en)	2013-06-06	2021-04-06	Amarin Pharmaceuticals Ireland Limited	Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en)	2013-09-04	2015-03-05	Amarin Pharmaceuticals Ireland Limited	Methods of treating or preventing prostate cancer
US9585859B2 (en)	2013-10-10	2017-03-07	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
KR101467853B1 (ko) *	2014-04-01	2014-12-03	창성소프트젤 주식회사	탄성 및 접착성이 우수하고 얇은 피막으로 생산성과 붕해도가 향상되는 식물성 연질캡슐 및 그의 조성물과 그 제조방법
US20150335586A1 (en) *	2014-05-20	2015-11-26	R.P. Scherer Technologies, Llc	Capsule dispensing container
US10561631B2 (en)	2014-06-11	2020-02-18	Amarin Pharmaceuticals Ireland Limited	Methods of reducing RLP-C
US10172818B2 (en)	2014-06-16	2019-01-08	Amarin Pharmaceuticals Ireland Limited	Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
BR112017008715A2 (pt) *	2014-10-31	2018-01-30	Barleans Organic Oils Llc	método e aparelho para a fabricação de cápsulas moles
EP4360653A3 (en) *	2015-03-26	2024-07-31	Patheon Softgels Inc.	Liquisoft capsules
KR101655407B1 (ko) *	2015-09-02	2016-09-08	주식회사 아미코스메틱	마이크로 캡슐, 및 마이크로 캡슐을 포함하는 화장료 조성물
US10406130B2 (en)	2016-03-15	2019-09-10	Amarin Pharmaceuticals Ireland Limited	Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2018213663A1 (en)	2017-05-19	2018-11-22	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides in a subject having reduced kidney function
MX2017016719A (es) *	2017-12-19	2020-01-20	Alepharma Soc Anonima Promotora De Inversion De Capital Variable	Composición farmacéutica combinada para la prevención de la formación de productos finales de la glicación avanzada.
US11058661B2 (en)	2018-03-02	2021-07-13	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
MA51766A (fr)	2018-09-24	2020-12-16	Amarin Pharmaceuticals Ie Ltd	Procédés de réduction du risque d'événements cardiovasculaires chez un sujet
BR112022009189A2 (pt)	2019-11-12	2022-07-26	Amarin Pharmaceuticals Ie Ltd	Métodos para reduzir o risco de eventos cardiovasculares em um sujeito com fibrilação atrial e/ou palpitação atrial
KR102412895B1 (ko)	2020-03-03	2022-07-06	주식회사 휴온스메디컬	시린지의 플런저 고정장치
CN114983962B (zh) *	2021-03-02	2024-03-15	仙乐健康科技股份有限公司	软胶囊囊壳组合物、软胶囊和其制备方法和用途
US11986452B2 (en)	2021-04-21	2024-05-21	Amarin Pharmaceuticals Ireland Limited	Methods of reducing the risk of heart failure

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3173840A (en) *	1962-04-30	1965-03-16	Lilly Co Eli	Separation-resistant capsule
US3927195A (en) *	1974-01-31	1975-12-16	Lilly Industries Ltd	Production of capsules
JPH089536B2 (ja) *	1987-10-30	1996-01-31	日清製粉株式会社	腸溶性カプセルの製造方法
US4954346A (en) *	1988-06-08	1990-09-04	Ciba-Geigy Corporation	Orally administrable nifedipine solution in a solid light resistant dosage form
JPH04288011A (ja) *	1991-03-14	1992-10-13	Tokai Capsule Kk	軟カプセル剤
JPH0565222A (ja) *	1991-09-09	1993-03-19	Fuji Capsule Kk	カプセル剤用プルラン配合皮膜及びカプセル剤
DE69732909T2 (de) *	1996-07-12	2005-08-11	Daiichi Pharmaceutical Co., Ltd.	Rasch zerfallende Pressmasse und Verfahren zu ihrer Herstellung
JP3261331B2 (ja) *	1997-03-31	2002-02-25	東海カプセル株式会社	咀嚼用ソフトカプセル剤
JP2000128778A (ja) *	1998-10-20	2000-05-09	Tokai Capsule Kk	捩じり切り開披型ソフトカプセル
KR100759771B1 (ko) *	2000-07-18	2007-10-04	오노 야꾸힝 고교 가부시키가이샤	성상세포 기능 개선제를 유효 성분으로 함유하는 파킨슨병치료제
JP4706950B2 (ja) *	2000-07-18	2011-06-22	小野薬品工業株式会社	アストロサイト機能改善剤を有効成分として含有するパーキンソン病治療剤
CA2453478A1 (en) *	2001-07-18	2003-01-30	Ono Pharmaceutical Co., Ltd.	Agent for treatment of cerebral ischemic diseases
US20050058703A1 (en) *	2003-08-01	2005-03-17	Chang Robert C.	Gelatin capsules
ES2390055T3 (es) *	2003-10-03	2012-11-06	Ono Pharmaceutical Co., Ltd.	Fármaco que contiene ácido(2R)-2-propiloctanoico como principio activo

2005
- 2005-06-09 TW TW094119016A patent/TW200613009A/zh unknown
- 2005-06-10 KR KR1020077000705A patent/KR20070024722A/ko not_active Withdrawn
- 2005-06-10 EP EP05751213A patent/EP1754479A4/en not_active Withdrawn
- 2005-06-10 MX MXPA06014396A patent/MXPA06014396A/es not_active Application Discontinuation
- 2005-06-10 RU RU2006147223/15A patent/RU2384325C2/ru not_active IP Right Cessation
- 2005-06-10 CA CA002569746A patent/CA2569746A1/en not_active Abandoned
- 2005-06-10 AU AU2005251623A patent/AU2005251623A1/en not_active Abandoned
- 2005-06-10 JP JP2006514617A patent/JP5615478B2/ja not_active Expired - Fee Related
- 2005-06-10 WO PCT/JP2005/011092 patent/WO2005120490A1/ja not_active Ceased
- 2005-06-10 BR BRPI0512000-4A patent/BRPI0512000A/pt not_active IP Right Cessation
- 2005-06-10 US US11/629,178 patent/US20080057115A1/en not_active Abandoned
2006
- 2006-12-08 NO NO20065670A patent/NO20065670L/no not_active Application Discontinuation
- 2006-12-11 IL IL179967A patent/IL179967A0/en unknown

Also Published As

Publication number	Publication date
RU2384325C2 (ru)	2010-03-20
US20080057115A1 (en)	2008-03-06
KR20070024722A (ko)	2007-03-02
EP1754479A4 (en)	2011-03-23
AU2005251623A1 (en)	2005-12-22
BRPI0512000A (pt)	2008-01-22
RU2006147223A (ru)	2008-07-20
WO2005120490A1 (ja)	2005-12-22
NO20065670L (no)	2007-03-12
EP1754479A1 (en)	2007-02-21
JPWO2005120490A1 (ja)	2008-04-03
JP5615478B2 (ja)	2014-10-29
CA2569746A1 (en)	2005-12-22
IL179967A0 (en)	2007-05-15
MXPA06014396A (es)	2007-03-12

Publication	Publication Date	Title
NO20065670L (no)	2007-03-12	Kapsel som er stabil mot mastikasjon.
Dellabella et al.	2005	Medical-expulsive therapy for distal ureterolithiasis: randomized prospective study on role of corticosteroids used in combination with tamsulosin—simplified treatment regimen and health-related quality of life
ES2238770T5 (es)	2012-01-17	Utilización de inhibidores del sistema renina-angiotensina para el tratamiento de la hipoxia o de la disminución de la función metabólica.
NZ607189A (en)	2015-04-24	Materials and methods for improving gastrointestinal function
GEP20156281B (en)	2015-05-11	Orally administered corticosteroid compositions
TW200509923A (en)	2005-03-16	A novel formulation, omeprazole antacid complex-immediate release, for rapid and sustained suppression of gastric acid
ES2954984T3 (es)	2023-11-28	Composiciones y procedimientos sinérgicos de tratamiento del glicocálix
CN109789162A (zh)	2019-05-21	具有降低的纤溶活性的人类血液源产品及其在止血障碍中的用途
DE602007001467D1 (de)	2009-08-20	Therapeutische Zubereitung von hochreinem FVIIa und Verfahren zu dessen Gewinnung
Gordjani et al.	1997	Hemolytic uremic syndromes in childhood
Rasmussen	2022	An overview of pediatric peritoneal dialysis and renal replacement therapy in infants: A review for the general pediatric surgeon
Rees et al.	1992	Do patients with moderately impaired gastrointestinal function requiring enteral nutrition need a predigested nitrogen source? A prospective crossover controlled clinical trial.
Tiev et al.	2011	Digestive tract involvement in systemic sclerosis
CN104602701B (zh)	2019-04-16	作为抗纤维蛋白溶解剂的纤维蛋白溶酶原活化剂的突变体
EA200500031A1 (ru)	2005-08-25	Быстрораспадающаяся таблетка
AU3091997A (en)	1998-06-22	Composition for producing a long-lasting satiation effect
EP2098225B8 (en)	2011-06-22	Taste masking system for non-plasticizing drugs
Dorothy McComb	1998	Gallium restorative materials
EP1924278A2 (en)	2008-05-28	A kit of lyophilized thrombin and lyophilized fibrinogen used to compound fibrin membrane, and its application
WO2010111215A3 (en)	2011-02-03	Compositions and methods for treatment of hemorrhage
WO2006023295A3 (en)	2007-03-08	Pharmaceutical compositions comprising effervescent agents and fenofibrate
Sharma et al.	2006	Pancake kidney detected on renal scintigraphy
RU2524799C1 (ru)	2014-08-10	Способ эндотелиопротекции апи-фитокомпозицией
Marshall	2014	Alterations in the brain renin-angiotensin system in a model of fetal programming
Smart	1978	The problems of patients with cardiovascular disease undergoing dental treatment: GLASSER SPJ Am. Dent. Assoc. 94 (1977) 1158–1162